We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App




CO-Oximetry External QA Programme Launched

By LabMedica International staff writers
Posted on 22 Mar 2018
Co-oximetry is a methodology that measures the levels of the oxygen-carrying protein haemoglobin, which is the chief component of red blood cells and CO-oximetry is useful in defining the causes for hypoxemia, or hypoxia.

Co-oximetry is a useful tool in that it helps determine the levels of various forms of haemoglobin and can be used to diagnose a variety of conditions related to oxygen content in blood. More...
Oxygen content is an important indicator of oxygen transport within the body. The oxygen transport of arterial blood is used to evaluate the ability of transporting oxygen from the lungs to the tissue.

A new CO-Oximetry programme to complement their existing Blood Gas programme has been launched by Randox (Crumlin, UK). The programme combines seven parameters in a user-friendly, liquid ready-to-use format, the new RIQAS CO-Oximetry External Quality Assessment (EQA) programme has been designed with consolidation and convenience in mind and it is even suitable for use in point-of-care testing. All samples are supplied in a liquid ready-to-use format ideal for both clinical and point-of-care testing.

The seven parameters covered by the programme are: Carboxyhaemoglobin (COHb / HbCO); Methaemoglobin (MetHb); Oxygen Content (O₂CT); Oxygen Saturation (sO₂ / Vol O₂); Oxyhaemoglobin (O₂Hb / HbO₂); Total Haemoglobin (tHb); and Reduced / Deoxyhaemoglobin (RHb / HHb). A high value for the Co-Oximetry Blood Test may indicate, among other things: carbon monoxide poisoning or congenital haemoglobin disorder. To compliment the RIQAS CO-Oximetry EQA Programme, the RIQAS Blood Gas EQA programme incorporates 10 parameters into a liquid ready-to-use format for ease of use.

RIQAS is the world’s largest EQA scheme with 45,000 participants and 33 programmes ensuring peer groups are maximised. Lynsey Adams, BSc, the Quality Control Marketing Manager at Randox, said, “The launch of our new CO-Oximetry programme means we now offer a complete EQA solution for blood gas testing.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
All-in-One Molecular System
AIO M160
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.